Efficacy of vitamin C in prevention of mucositis
Not Applicable
- Conditions
- Head and neck cancer.Neoplasm of uncertain or unknown behaviour of other and unspecified sitesC00-D48
- Registration Number
- IRCT2015112525239N1
- Lead Sponsor
- Vice chancellor for research, Tabriz University Of Medical Sciences.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
age between 15 to 70 years; Cisplatin regimen with 45-60 Gy radiation.
Exclusion criteria: any oral disease like oral active infections; candidiasis; artificial teeh; using tobacco; smoking; alcohol use; using opioids; and fever more than 38.5 ° C.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of mucositis. Timepoint: weekly for 4 weeks. Method of measurement: WHO Toxicity Criteria.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie vitamin C's anti-inflammatory effects in chemoradiation-induced mucositis?
How does vitamin C compare to amifostine in preventing mucositis in head and neck cancer patients (IRCT2015112525239N1)?
Are there specific biomarkers like IL-8 or TGF-β that predict mucositis response to vitamin C therapy?
What adverse events are associated with high-dose vitamin C in head and neck cancer patients undergoing chemoradiation?
What combination therapies involving vitamin C and glutamine show enhanced mucositis prevention in oncology trials?